Tags

Type your tag names separated by a space and hit enter

Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia.
Curr Med Res Opin. 2007 Oct; 23(10):2585-96.CM

Abstract

OBJECTIVE

To estimate the cost-effectiveness of branded pregabalin (PGB) versus generic gabapentin (GBP) in patients with neuropathic pain (NeP) due to painful diabetic polyneuropathy (DPN) or post-herpetic neuralgia (PHN) in Spain.

METHODS

Using stochastic simulation, we estimated the cost-effectiveness of PGB 150-600 mg/d vs. GBP 900-3600 mg/d in a hypothetical cohort of 1000 patients. The model used data from three randomized controlled clinical trials. Pain was evaluated using a 0-10 scale. Mean baseline pain was 6.9 in both treatment groups. The model assigned untreated pain scores over 84 days. Treated scores were calculated using weekly changes in pain scores from trials. Outcomes included the numbers of days with no or mild pain (score < 4), days with >or= 30% and >or= 50% reductions in pain intensity, quality-adjusted life-years (QALYs), and estimated health costs.

RESULTS

Compared with GBP, PGB yielded an estimated mean of 8 (standard error, 0.4) additional days with no or mild pain, 6 (0.4) days with >or= 30% reduction in pain intensity, 9 (0.5) days with >or= 50% reduction in pain intensity, and a gain of 0.1186 (0.0002) QALYs for 12 weeks. The estimated total health costs of therapies were euro 1049 (euro 35) for PGB and euro 951 (euro 38) for GBP, respectively. Incremental cost-effectiveness ratio (ICER) for PGB versus GBP were a mean of euro 12 (95% confidence interval, euro 1-24) per additional day with no or mild pain, euro 431 (dominant-euro 876) per additional patient with no or mild pain, and euro 20 535 (euro 1607-40 345) per QALY gained.

CONCLUSIONS

According with data used in this modeling in patients with NeP due to DPN and/or PHN, PGB was shown to be more cost-effective than generic gabapentin in Spain.

Authors+Show Affiliations

Pain and Palliative Care Unit, Carlos Haya University Hospital, Málaga, Spain. maje1946@yahoo.esNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17875242

Citation

Rodríguez, M J., et al. "Cost-effectiveness Analysis of Pregabalin Versus Gabapentin in the Management of Neuropathic Pain Due to Diabetic Polyneuropathy or Post-herpetic Neuralgia." Current Medical Research and Opinion, vol. 23, no. 10, 2007, pp. 2585-96.
Rodríguez MJ, Díaz S, Vera-Llonch M, et al. Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia. Curr Med Res Opin. 2007;23(10):2585-96.
Rodríguez, M. J., Díaz, S., Vera-Llonch, M., Dukes, E., & Rejas, J. (2007). Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia. Current Medical Research and Opinion, 23(10), 2585-96.
Rodríguez MJ, et al. Cost-effectiveness Analysis of Pregabalin Versus Gabapentin in the Management of Neuropathic Pain Due to Diabetic Polyneuropathy or Post-herpetic Neuralgia. Curr Med Res Opin. 2007;23(10):2585-96. PubMed PMID: 17875242.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia. AU - Rodríguez,M J, AU - Díaz,S, AU - Vera-Llonch,M, AU - Dukes,E, AU - Rejas,J, PY - 2007/9/19/pubmed PY - 2007/12/15/medline PY - 2007/9/19/entrez SP - 2585 EP - 96 JF - Current medical research and opinion JO - Curr Med Res Opin VL - 23 IS - 10 N2 - OBJECTIVE: To estimate the cost-effectiveness of branded pregabalin (PGB) versus generic gabapentin (GBP) in patients with neuropathic pain (NeP) due to painful diabetic polyneuropathy (DPN) or post-herpetic neuralgia (PHN) in Spain. METHODS: Using stochastic simulation, we estimated the cost-effectiveness of PGB 150-600 mg/d vs. GBP 900-3600 mg/d in a hypothetical cohort of 1000 patients. The model used data from three randomized controlled clinical trials. Pain was evaluated using a 0-10 scale. Mean baseline pain was 6.9 in both treatment groups. The model assigned untreated pain scores over 84 days. Treated scores were calculated using weekly changes in pain scores from trials. Outcomes included the numbers of days with no or mild pain (score < 4), days with >or= 30% and >or= 50% reductions in pain intensity, quality-adjusted life-years (QALYs), and estimated health costs. RESULTS: Compared with GBP, PGB yielded an estimated mean of 8 (standard error, 0.4) additional days with no or mild pain, 6 (0.4) days with >or= 30% reduction in pain intensity, 9 (0.5) days with >or= 50% reduction in pain intensity, and a gain of 0.1186 (0.0002) QALYs for 12 weeks. The estimated total health costs of therapies were euro 1049 (euro 35) for PGB and euro 951 (euro 38) for GBP, respectively. Incremental cost-effectiveness ratio (ICER) for PGB versus GBP were a mean of euro 12 (95% confidence interval, euro 1-24) per additional day with no or mild pain, euro 431 (dominant-euro 876) per additional patient with no or mild pain, and euro 20 535 (euro 1607-40 345) per QALY gained. CONCLUSIONS: According with data used in this modeling in patients with NeP due to DPN and/or PHN, PGB was shown to be more cost-effective than generic gabapentin in Spain. SN - 1473-4877 UR - https://www.unboundmedicine.com/medline/citation/17875242/Cost_effectiveness_analysis_of_pregabalin_versus_gabapentin_in_the_management_of_neuropathic_pain_due_to_diabetic_polyneuropathy_or_post_herpetic_neuralgia_ L2 - https://www.tandfonline.com/doi/full/10.1185/030079907X233151 DB - PRIME DP - Unbound Medicine ER -